Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals

• Status: Unknown status
• Trial end date: 2020-12-31

Summary

This study aims to screen and validate multi-scale bio-markers for early diagnosis and medication monitoring for early schizophrenia, including the genetic, neurobiochemistry, neuroimaging and eletrophysiological measures. Based on the validated bio-markers, the present study further tries to build several prediction models for early differential diagnosis of schizophrenia from healthy controls and other mental diseases (such as the major depression and anxiety disorders), biological sub-typing and diagnosis of the schizophrenia sub-types, and early prediction of the medication effects.

• Phase: Early Phase 1

Details

• Lead Sponsor: Tianjin Medical University General Hospital
• Collaborators: Anhui Mental Health Center; First Affiliated Hospital of Chongqing Medical University; First Affiliated Hospital of Harbin Medical University; Harbin First Specialist Hospital; Nanjing Brain Hospital Affiliated to Nanjing Medical University; Nanjing Medical University; Shanghai Mental Health Center; Tianjin Anding Hospital; Wenzhou Seventh People's Hospital; Wuhan Psychiatric Hospital
• Treatments: Aripiprazole; Olanzapine; Risperidone